It’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19 variants as they pop up.
But with challenges, comes opportunities to learn and grow. So as the end of the year approaches, we took the chance to tap our client list and ask CEOs of ASX-listed small caps – from sand miners to cannabis growers to fintechs – what they learnt in 2021, their highlights, and what they hope for in 2022.
Our focus is on revenue growth by acquiring new banks and fintech clients and
Building our partnership model with complementary organisations
Working closely with schemes like Mastercard and Visa to enable high demand payments functionality to address the changing consumer led disruption in the payments industry
We’ll continue the development of our second-generation TALi platform, which will be rolled out in the U.S. in 2023 by Akili for children aged 3-8.
We’ll also work to put our first-generation products, TALi Detect and TALi Train, in the hands of more parents, children and healthcare professionals.
We’ll continue to work with the community help reduce the remaining stigma about attention challenges in children. We know from research that it’s possible to ‘retrain’ our brains. That’s all the more true in young children. In TALi we now have digital ‘medicines’ which can help improve attention. But, as the saying goes, the first step is always admitting there is a problem. As a community we still have some way to go there.
For ActivePort, 2022 will be the year of international growth. We’ve done the groundwork setting up international partnerships and a strong customer base, and next year we will see the results of our strategy.
We have three main goals: Execute our hunt for top talent in Australia and overseas, drive an excellent and seamless customer experience, and converting our strong customer pipeline to deliver strong revenue growth in software sales. I am looking forward to being able to tell the story of how we’re growing in 2022.
Brand leadership through product innovation and a continued focus on quality
Continuing to build a performance based culture
Steven Yatomi-Clarke (CEO, Prescient Therapeutics, ASX:PTX)
Progress our targeted therapies through the clinic, with PTX-100 in particular showing encouraging signs in a high value disease with unmet need (PTCL)
Ongoing development of three OmniCAR products for next-generation cell therapies in AML; GBM and Her2+ solid cancers
Leveraging the unique capabilities of the OmniCAR platform beyond our programs to create truly game-changing cell therapies
We are an Australian based technology company, but our product is global. We play in a global market space into the Billions of dollars and we can create our own global market. We’re focussed on ‘what’s Next!’
Hybrid cloud helps to bridge the gap between businesses and information technology by improving efficiency and agility and at the same time rapidly delivering IT resources at an affordable cost, our focus is to continue to expand into new locations and secure enterprise contracts.
Becoming a profitable company and being cashflow positive
Completing the Epilepsy studies and getting CannEpil to the finish line so we can get to the stage where we can be in talks with drug agencies to commercialise it
Deliver on the guidance we gave to the market about strong revenue growth for our FY2022. Our guidance at the start of the financial year was for revenue of NZ$25M to $NZ26M. In the first half, revenue was up 30 per cent to $NZ12.3M. The second half is traditionally stronger, so we’re well positioned
Continue to innovate. We have successfully piloted “Project Thumb”, which is a move towards empowering women with breast density information by including their images directly into their notification letters. We have numerous other initiatives in various stages of development or roll out, including building out our extensive data platform. We continue to work with researchers around the world to help them understand what optimal breast cancer screening might look like. We have so much more that we can do to reduce the cancer death toll
Continue to become ever more scalable in all that we do. Last year, we reworked our underlying on-site architecture to allow it to scale much more easily and cost-effectively as our footprint grows. And this year the focus on scalability came to fruition with the release of a significantly upgraded version of our key cloud product, Volpara Analytics
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.